Dick Cheney
This article was originally published in The Gray Sheet
Executive Summary
Republican vice presidential nominee is treated with Guidant's MultiLink Tetra coronary stent Nov. 22 at the George Washington University Hospital in Washington, D.C., according to company officials. The fourth-generation stent received PMA supplement approval Oct. 3 (1"The Gray Sheet" Oct. 9, 2000, p. 16)
You may also be interested in...
Guidant Tetra Stent Approval Opens Opportunity To Recoup Lost Market Share
Guidant is looking to its Multi-Link Tetra fourth-generation coronary stent platform to recoup a recent loss in U.S. stent market share, following a drop-off in demand for its Tri-Star stent.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.